Bai, Yu
Zhang, Xin
Zheng, Jie
Liu, Ziyi
Yang, Zhenfan
Zhang, Xiaolin
Article History
Received: 2 September 2022
Accepted: 3 October 2022
First Online: 14 October 2022
Declarations
:
: All studies involving animals were conducted according to the guidelines approved by Institutional Animal Care and Use Committees (IACUC) and the standard and local regulatory requirements of Dizal Pharmaceuticals. The Phase 1 study was conducted in the United States in accordance with the Good Clinical Practice (GCP) and applicable regulatory requirements. Informed consent was obtained from all individual participants in the study.
: Not applicable.
: DZD2269 is an investigational drug of Dizal Pharmaceuticals, and currently in clinical evaluation. All authors are or have been employees and shareholders of Dizal Pharmaceuticals.
: <sup>1</sup>Biomed-X Center, Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, 100871, China. <sup>2</sup>Dizal Pharmaceuticals, Shanghai, 201203, China.